Eledon Pharmaceuticals Inc (ELDN) - Total Liabilities
Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has total liabilities worth $100.82 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eledon Pharmaceuticals Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Eledon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Eledon Pharmaceuticals Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Eledon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Colonial Coal International Corp
V:CAD
|
Canada | CA$106.36K |
|
Cahya Mata Sarawak Bhd
KLSE:2852
|
Malaysia | RM801.52 Million |
|
Karmarts Public Company Limited
BK:KAMART
|
Thailand | ฿1.37 Billion |
|
AVCON Information Tech
SHE:300074
|
China | CN¥509.97 Million |
|
Lineage Cell Therapeutics Inc
NYSE MKT:LCTX
|
USA | $68.84 Million |
|
XinJiang GuoTong Pipeline Co Ltd
SHE:002205
|
China | CN¥3.40 Billion |
|
Celon Pharma SA
WAR:CLN
|
Poland | zł141.95 Million |
|
Myoung Shin Industrial Co Ltd
KO:009900
|
Korea | ₩627.11 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Eledon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Eledon Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eledon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eledon Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Eledon Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $100.82 Million | +70.12% |
| 2024-12-31 | $59.27 Million | +39.53% |
| 2023-12-31 | $42.48 Million | +393.32% |
| 2022-12-31 | $8.61 Million | +31.39% |
| 2021-12-31 | $6.55 Million | -0.55% |
| 2020-12-31 | $6.59 Million | +349.45% |
| 2019-12-31 | $1.47 Million | -42.15% |
| 2018-12-31 | $2.53 Million | +75.97% |
| 2017-12-31 | $1.44 Million | -50.40% |
| 2016-12-31 | $2.90 Million | -53.55% |
| 2015-12-31 | $6.25 Million | +47.30% |
| 2014-12-31 | $4.24 Million | -95.15% |
| 2013-12-31 | $87.55 Million | +68.82% |
| 2012-12-31 | $51.86 Million | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more